PineBridge Investments L.P. raised its stake in shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) by 4.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,681 shares of the company’s stock after buying an additional 154 shares during the period. PineBridge Investments L.P.’s holdings in Integra LifeSciences Holdings Corp. were worth $293,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in IART. Suntrust Banks Inc. boosted its stake in shares of Integra LifeSciences Holdings Corp. by 0.4% in the second quarter. Suntrust Banks Inc. now owns 4,758 shares of the company’s stock valued at $379,000 after buying an additional 20 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Integra LifeSciences Holdings Corp. by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,900 shares of the company’s stock valued at $1,029,000 after buying an additional 100 shares during the period. Cardinal Capital Management boosted its stake in Integra LifeSciences Holdings Corp. by 5.1% in the second quarter. Cardinal Capital Management now owns 6,228 shares of the company’s stock valued at $497,000 after buying an additional 301 shares during the period. Cambridge Trust Co. boosted its stake in Integra LifeSciences Holdings Corp. by 6.3% in the second quarter. Cambridge Trust Co. now owns 8,300 shares of the company’s stock valued at $662,000 after buying an additional 495 shares during the period. Finally, Diversified Trust Co boosted its stake in Integra LifeSciences Holdings Corp. by 10.3% in the second quarter. Diversified Trust Co now owns 7,500 shares of the company’s stock valued at $598,000 after buying an additional 700 shares during the period. 88.32% of the stock is owned by institutional investors.

Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) opened at 87.285 on Thursday. The firm’s 50-day moving average is $85.54 and its 200-day moving average is $75.83. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of 360.682 and a beta of 0.52. Integra LifeSciences Holdings Corp. has a 12-month low of $54.75 and a 12-month high of $88.86.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its earnings results on Thursday, July 28th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. The company earned $249.30 million during the quarter, compared to analysts’ expectations of $243.17 million. Integra LifeSciences Holdings Corp. had a net margin of 0.79% and a return on equity of 15.41%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 earnings per share. Equities research analysts forecast that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current fiscal year.

Several analysts have recently weighed in on the stock. Piper Jaffray Cos. reissued an “overweight” rating and issued a $94.00 price target (up previously from $86.00) on shares of Integra LifeSciences Holdings Corp. in a research note on Sunday, August 21st. Zacks Investment Research cut shares of Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Jefferies Group increased their price target on shares of Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Barclays PLC increased their price target on shares of Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the company an “equal weight” rating in a research note on Friday, July 29th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They issued an “overweight” rating for the company. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $83.43.

In other Integra LifeSciences Holdings Corp. news, Director Raymond G. Murphy sold 2,600 shares of Integra LifeSciences Holdings Corp. stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $86.64, for a total transaction of $225,264.00. Following the completion of the transaction, the director now owns 33,047 shares in the company, valued at $2,863,192.08. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Peter J. Arduini sold 24,009 shares of Integra LifeSciences Holdings Corp. stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $84.52, for a total transaction of $2,029,240.68. Following the transaction, the chief executive officer now owns 29,602 shares of the company’s stock, valued at approximately $2,501,961.04. The disclosure for this sale can be found here. Company insiders own 22.00% of the company’s stock.

Integra LifeSciences Holdings Corp. Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corp. (NASDAQ:IART).

Receive News & Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.